Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta by Zecca, Chiara et al.
 
Treatment satisfaction, adherence and behavioral assessment in
patients de – escalating from natalizumab to interferon beta
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Zecca, Chiara, Gianna C Riccitelli, Pasquale Calabrese,
Emanuele Pravatà, Ursula Candrian, Charles RG Guttmann, and
Claudio Gobbi. 2014. “Treatment satisfaction, adherence and
behavioral assessment in patients de – escalating from
natalizumab to interferon beta.” BMC Neurology 14 (1): 38.
doi:10.1186/1471-2377-14-38. http://dx.doi.org/10.1186/1471-
2377-14-38.
Published Version doi:10.1186/1471-2377-14-38
Accessed February 19, 2015 3:47:44 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12064548
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH ARTICLE Open Access
Treatment satisfaction, adherence and behavioral
assessment in patients de – escalating from
natalizumab to interferon beta
Chiara Zecca
1, Gianna C Riccitelli
1, Pasquale Calabrese
2, Emanuele Pravatà
1, Ursula Candrian
1,
Charles RG Guttmann
3 and Claudio Gobbi
1*
Abstract
Background: De-escalating natalizumab (NTZ) to interferon beta 1b (IFN B 1B) is a possible treatment option in
multiple sclerosis (MS) patients interrupting NTZ because of increased risk of progressive multifocal
leukoencephalopathy (PML). The aim of this study was to evaluate satisfaction and adherence to treatment,
behavioral and fatigue changes in patients switched to IFN B 1B compared to continued NTZ treatment.
Methods: A 1 year, prospective, randomized, rater-blinded, parallel-group study. Nineteen relapsing remitting (RR)
MS patients, randomly assigned to undergo either NTZ (n = 10) or IFN B 1B (n = 9) treatment, who had previously
received NTZ for at least 12 months with disease stability and fearing or at risk for PML were included. Patients
underwent behavioral and treatment assessments at baseline, after 24-week and 1 year follow-up. Behavioral
assessment included measures of cognition, fatigue and quality of life. Treatment assessment included measures
of satisfaction, persistence and adherence to treatment. Clinical-radiological disease activity and safety were
also assessed.
Results: Baseline characteristics of patients were similar between groups except for Euro Quality Visual Analogue
Scale, being higher in the NTZ group (p = 0.04). Within-group comparisons at the three time points, as well as
interaction analysis of treatment effect over time did not show any statistically significant differences in behavioral
or treatment assessments, but a coherent trend favoring NTZ over IFN B 1B.
Conclusions: De-escalating NTZ to IFN B 1B is feasible and associated with overall good patient related outcome
and persistently stable behavioral measures.
Keywords: Adherence, Fatigue, Cognition, Quality of life, Multiple sclerosis, Natalizumab, Interferon beta-1b
Background
Interferon beta (IFN B 1B) and glatiramer acetate (GA)
are the most widely prescribed first line disease modifying
drugs for relapsing remitting multiple sclerosis (RRMS).
They have proven to be efficacious in reducing relapse
frequency and disability progression in the short term.
NTZ, a novel drug approved in Europe as second line
therapy, exerts a robust anti-inflammatory activity in
RRMS, but is associated with an increased risk of progres-
sive multifocal leukoencephalopathy (PML) [1-8] which
limits its prolonged use in the majority of cases. However,
NTZ cessation is followed by a reactivation of disease ac-
tivity [9] and no established guidelines exist on patient risk
stratification and management. A few recent reports have
explored the possible role of first line MS disease modify-
ing therapies as de-escalating compounds after NTZ
cessation [10-12], showing a moderate capability to limit
recrudescence of disease activity. Besides efficacy, patient-
reported outcomes (PRO) are crucial when addressing
the selection of a specific treatment, especially in the long
term. Here we present changes in treatment satisfaction
and adherence, as well as in behavioral assessments in-
cluding measures of cognitive functions, fatigue and
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small group of patients in clinical practice.
Methods
Ethics statement
The study protocol was approved by the local ethics com-
mittee (Comitato Etico Cantonale del Canton Ticino) and
Swissmedic, and conducted in accordance with the ethical
principles of the Declaration of Helsinki and the ICH-
GCP Guidelines of 17 Jan. 1997 (G.U. n 191, 18 Ago
1997) and with the appropriate national regulations. Pa-
tients provided written informed consent before study
enrollment.
General study description
This is a pre-planned analysis of the study reported at
ClinicalTrial.gov ID: NCT1144052, testing the employ-
ment of IFN B 1B as a de-escalating option following
NTZ treatment. The design and clinico-radiological effi-
cacy results have been previously described in detail [12].
The trial was a 1-year, prospective, controlled, ran-
domized, rater blinded, parallel-group, monocentric pilot
study that included 19 patients with RRMS according to
2005 McDonald criteria [13] from 2010 to 2011. Main
inclusion criteria were age between 18 and 60, being at
significant risk for (i.e. NTZ treatment duration equal to
or greater than 12 months) or fear of PML, and being
free of disease activity (free from relapses and disability
progression for at least 6 months and no gadolinium
enhancing lesions [Gd +L] on baseline [BL] MRI). In-
cluded patients were randomly assigned in a 1:1 ratio to
continue monthly intravenous (i.v.) NTZ 300 mg or to
de-escalate to subcutaneous (s.c.) IFN B 1B 250 μg every
other day. The study was powered for MRI outcomes.
Here we report the secondary and tertiary outcomes.
Complete behavioral assessment, treatment satisfaction,
persistence and adherence over 1 year were evaluated in
the de–escalation group and compared to continued NTZ
treatment.
Behavioral assessment
At baseline (t0), 6 months (t1) and 1 year (t2), behavioral
assessment of patients included Paced Auditory Serial
Addition Test, 3 sec (PASAT), Fatigue Scale for Motor
and Cognitive functions (FSMC), Functional Assessment
of Multiple Sclerosis (FAMS), and EuroQuol visual
analogue scale (EQ-VAS).
The PASAT is a measure of sustained attention and
speed of information processing [14]. This test is widely
used in many cognitive research batteries for MS and
is included in formal clinical outcome measures such
as the MS Functional Composite Measure [15]. To avoid
as much as possible a “practice effect” on the cognitive
outcomes, parallel forms (form A and form B) of tests
were alternatively administered at consecutive cognitive
evaluations.
The FSMC is a self-administered and validated ques-
tionnaire specifically developed for MS related fatigue
symptoms [16]. It consists of 20 items and allows gradu-
ation of fatigue severity, and separate evaluation of
motor (10 items) and cognitive (10 items) fatigue com-
ponents. Each question is rated on a five-point Likert
scale. A total score greater than 43 indicates the pres-
ence of fatigue and the score increases proportionally to
the severity of fatigue up to a maximum score of 100.
The FAMS consists of a generic core health-related
quality of life (QoL) measure, supplemented with MS spe-
cific items [17]. A total score for overall QoL is derived by
adding the scores for all subscales excluding ‘additional
concerns’. It ranges from 0 to 176, and a higher score re-
flects a better QoL [17].
The EQ-VAS is the last component of EQ-5D (Euro-
Quol 5 dimension), a brief standardized and generic
measure of health-related QoL that provides a functional
profile of an individual patient and a global health state
rating [18]. EQ-VAS consists of a 10 centimetres visual
analogue scale (VAS). The respondents can report their
perceived health status ranging from 0 (worst imaginable
health state) to 100 (best imaginable health state).
Treatment assessment
At t1 and t2 the treatment satisfaction (TS) was quanti-
fied with TS-VAS, a 10 centimeters visual analogue scale
by which respondents can report their perceived satisfac-
tion related to therapy ranging from 0 (worst satisfac-
tion) to 100 (best satisfaction).
In all patients the persistence on treatment and the ad-
herence to therapy were reported. Persistence on treat-
ment was measured as percentage of patients remaining
on treatment for the whole evaluation period, and adher-
ence to the therapy was defined as the ratio between the
number of administered injections (or infusions) and the
approved dosage [19,20]. Data were obtained from drug
accountability at study site.
Clinical-radiological assessments and safety
Complete clinical-radiological methods have been previ-
ously published by our group [12]. Patients were evaluated
every three months with Expanded Disability Status Scale
(EDSS) [21], and brain MRI [22]. Quarterly physical exam-
ination, registration of local and systemic adverse events,
laboratory analysis as well as brain MRI were part of the
safety follow-up. Clinical evaluation and brain MRI were
performed in any case of neurological deterioration.
Statistical analysis
Baseline demographic and clinical measures were com-
pared between groups using the Two-sided exact Fisher
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tudinal generalized linear models for repeated measures
were used to assess changes of neuropsychological/behav-
ioral performance over time based on Poisson distribu-
tion. An unstructured covariance matrix was used to
model the repeated measurements. We tested specific
contrast: t1 vs t0, t2 vs t0, and t2 vs t1, and we assessed an
overall time trend. Differential treatment effect over time
was assessed including the group x time interaction term
into the models. Given the small samples size we applied a
correction for Type I error using for each neuropsycho-
logical end point an adjustment for multiple comparisons
following the Bonferroni method. Statistical analyses were
performed using the SPSS 13.0 software package (SPSS
Inc., Chicago, IL, USA).
Results
Nineteen patients were included (NTZ =10, IFN B 1B=9).
Table 1 summarizes baseline measures related to
demographics and clinical parameters that were similar
between groups. At baseline, all clinical variables were
similar between groups (PASAT p =0.68, FSMC p=0.93,
FAMS p=0.33), except for EQ-VAS measure that was
lower in the IFN B 1B group (p= 0.04).
17/19 patients completed the study: one IFN B 1B-
patient withdrew consent (day 34) because she could not
comply with study procedures; one NTZ-patient opted
for an oral treatment (day 139). Patient (#9) switched
from IFN B 1B to rescue treatment with GA at day 69
due to systemic side effects.
Table 2 summarizes the results of behavioral evalu-
ation and treatment assessment in the two study groups
at the three time points.
Within-group comparisons of behavioral and treatment
assessments at t1 vs t0, t2 vs t0, and t2 vs t1 showed no
significant differences (p values ranging from 0.08 to 1).
The interaction analysis of treatment effect over time
showed no significant changes for cognitive function
(PASAT), fatigue (FSMC), and quality of life (FAMS, EQ-
VAS) (p=0.8, p=0.9, p=0.2, respectively), as well as
treatment satisfaction (TS-VAS) (p=0.6) (Figure 1).
Nonetheless, coherent trends in favor of NTZ were
observed for the majority of these outcomes. The main
reasons for treatment satisfaction were “convenience of
use” and “no MS illness recall” for NTZ and “optimal
safety” for IFN B 1B.
Persistence on treatment was 90% (9/10) for NTZ, and
78% for IFN B 1B (7/9).
Treatment adherence over the study period was high
overall and showed a similar trend between groups
(p=0.9, Table 2). Main reasons for missing IFN B 1B
injections were: “forget to administer” (75%) and “con-
comitant fever” (9%). One patient didn’t receive one
NTZ infusion because of concomitant hospitalization
for gastroenteritis.
Clinical-radiological outcomes have been reported in
detail in Gobbi et al. [12], and are summarized in Table 3.
Briefly, a trend towards a superior efficacy of NTZ com-
pared to IFN B 1B was found in the majority of the clin-
ical and radiological outcome parameters.
Adverse events were within the expected range in both
groups. Skin reactions occurred in 44% of patients in the
IFN B 1B group, and self-limiting infections occurred in
both groups at comparable rates (33% for IFN B 1B vs
50% for NTZ, p=0.65). None of the patients continuing
NTZ developed PML symptoms or signs during the
course of this study.
Discussion and conclusions
PML risk stratification in patients undergoing NTZ
treatment can be performed based on treatment dur-
ation, history of previous immunosuppression and, more
recently, on serology for JCV [3-6]. The decision to dis-
continue NTZ may be derived from an unfavorable risk/
benefit ratio calculated on the basis of probabilistic clin-
ical reasoning [23]. Patients may also independently
interrupt NTZ for fear of developing PML. Overall, in
clinical practice up to 60% of patients with JCV seroposi-
tivity discontinue treatment [23]. Recently, some studies
have been conducted that address the efficacy of first
line compounds for MS after NTZ discontinuation,
showing a partial efficacy for glatiramer acetate and IFN
B 1B [10,11]. Adherence to treatment and how treat-
ment might change the quality of life are key issues of
Table 1 Demographic and clinical characteristics of MS patients on account of treatment
IFN B 1B group (n=9) NTZ group (n=10) p-value
Women/men 3/6 6 /4 0.18
Mean age, (range) [years] 39 (24–48) 43 (20–60) 0.46
Median disease duration, (range) [years] 12 (2–23) 10 (5–17) 0.71
Median NTZ infusions (range) [years] 21 (12–49) 25.5 (13–45) 0.66
Annualized relapse rate during NTZ treatment 0 (0) 0 (0–1.3) 0.50
Median EDSS (range) [years] 3.0 (1.5-3.5) 3.0 (1.5-3.5) 0.71
Abbreviations: MS multiple sclerosis; NTZ natalizumab; IFN B 1B interferon; EDSS expanded disability status scale.
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IFN B 1B Group *p value NTZ group *p value **p values
Behavioural
assessment
t0 (SD) t1 (SD) t2 (SD) t1vs t0 t2 vs t0 t2 vs t1 Time trend t0 (SD) t1 (SD) t2 (SD) t1 vs t0 t2 vs t0 t2 vs t1 Time trend
PASAT 44.7 (6.9) 45.1 (7.8) 49.1 (8.3) 1 0.3 - 0.2 42.0 (11.1) 45.0 (9.6) 47.5 (8.3) 0.8 0.1 - 0.1 0.8
FSMC 59.4 (17.7) 62.9 (17.6) 68.9 (12.3) 0.7 0.2 - 0.08 55.5 (19.1) 49.8 (16.5) 53.1 (13.9) 0.5 1 - 0.4 0.9
FAMS 122.4 (26.9) 116.9 (32.1) 109.2 (25.3) 1 0.2 - 0.2 133.3 (21.5) 132.7 (17.4) 133.7 (15.4) 1 1 - 0.9 0.2
EQ-VAS 64.3 (13.5) 59.2 (12.8) 59.8 (11.3) 0.9 1 - 0.5 78.5 (8.9) 71.2 (16.8) 77.3 (9.8) 0.3 1 - 0.2 0.6
TS - 80.0 (11.1) 78.6 (10.2) - - 0.4 0.4 - 96.0 (6.9) 93.0 (7.3) - - 0.1 0.1 0.6
Adherence - 91.7 (7.33) 90.6 (5.7) - - 0.6 0.6 - 100 (.00) 99.2 (2.5) - - 0.3 0.3 0.9
*p= longitudinal generalized linear models; **p = group x time interaction.
Abbreviation: NTZ natalizumab; IFN B 1B interferon; EDSS expanded disability status scale; PASAT 3” paced auditory serial addition test 3 sec.; FSMC fatigue scale for motor and cognition functions; FAMS functional
assessment of multiple sclerosis; EQ-VAS euroQuol visual analogue; TS treatment satisfaction SD standard deviation.
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8patient outcomes in chronic conditions where long-term
treatments are required. The awareness of this concern
has grown among neurologists to such an extent that
patient-reported outcomes (PRO) are nowadays included
even in larger MS clinical trials (ClinicalTrials.gov ID
NCT00751881). To the best of our knowledge, no previous
report on satisfaction of patients de-escalating from
NTZ to a first line, injectable disease modifying agent
for MS is available.
Behavioral measures as well as treatment satisfaction
and adherence in the IFN B 1B group were comparable
to those in the group with continued NTZ treatment.
Overall, NTZ was coherently favored in the majority of
the outcomes, even though this trend did not reach
statistical significance in any of the measures taken
alone. A larger study would be necessary to validate
this finding.
We evaluated changes in cognitive performance in the
two groups over time. At study entry both groups
obtained high PASAT scores suggesting preserved orbito-
frontal pathways involved in working memory mainten-
ance, manipulation and monitoring processes. We then
found that both treatments were associated with non-
significant improvement of cognitive performances over
time. Our results are in line with Fischer’s findings [24],
showing a positive effect of IFN B 1B on cognitive do-
mains investigated also with the PASAT test in a wide
sample of RRMS patients. This result, however, differs
from previous studies [25], which found NTZ to be more
effective than IFN B 1B in reducing cognitive deterior-
ation. Several factors are likely to contribute to explain
discrepancies between our and previous findings, includ-
ing limited cognitive impairment at baseline, short dur-
ation of follow-up, and tests used for the assessment of
cognitive performance. A “practice effect” might have also
contributed, however the use of parallel forms of PASAT
should have mitigated it at least to some extent.
Table 3 Clinical and radiological study outcomes
IFN B 1B NTZ p-value
(n=9) (n= 10)
Number of relapses, median
(range)^
3 0 0.447
- month 1 to 6 2 0 (0)
- month 6 to 12 1 0 (0)
Proportion of relapse free
patients over the follow up
period (number)°
78% (7) 100% (10) 0.206
Annualized relapse rate
- during run-in period NTZ 0 (0) 0 (0–1.3) 0.497
EDSS
- at month 6 3.0 (1.5-3.5) 3.0 (1.5-3.5) 0.966
- at month 12 3.5 (1.5-3.5) 3.0 (1.5-3.5) 0.315
Number of new T2 lesions,
median (range) ^
- at month 6 1.5 (0–9) 0 (0–2) 0.043
- at month 12 0 (0–12) 0 (0) 0.234
Number of Gd enhancing
lesions, median (range) ^
- at month 6 0 (0–5) 0 (0) 0.442
- at month 12 0 (0–2) 0 (0–1) 0.694
^U-Mann Whitney test; °two-sided exact Fisher test.
Figure 1 Assessment of treatment satisfaction at month six and at year 1 of study in natalizumab (NTZ group) [dotted line] and
interferon (IFN B 1B group) [continuous line].
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after 6 and 12 months of NTZ de-escalation to IFN B1
B, and compared to continued NTZ treatment. The role
of interferons in MS fatigue is controversial. Some
authors found interferons to aggravate fatigue [26,27],
while others showed interferons to be irrelevant to
fatigue [28,29]. On the other hand, escalation to NTZ
has been shown to be associated with a perceived reduc-
tion of fatigue [30,31]. In our study, fatigue might have
been influenced by disease recurrence in some patients
in the IFN B 1B arm.
QoL on IFN B 1B was comparable to previous treat-
ment with NTZ and to continued NTZ therapy at 6 and
12 months’ time points. This result may be related to
the substantial satisfaction with the treatment expressed
by patients on IFN B 1B, which was similar to that of
the NTZ group (p =0.6). Interestingly, the main reasons
for treatment satisfaction were “convenience of use” and
“no MS illness recall” for NTZ and “optimal safety” for
IFN B 1B. Treatment safety remains a crucial concern
for patients undergoing NTZ treatment, and possibly
counterbalances the disadvantage of IFN B 1B adminis-
tration route and side effects, when assessing overall
quality of life. Indeed, in our clinical practice the fear of
PML is sometimes followed by development of disabling
mental distress ultimately associated to a significant
worsening of quality of life. Similar findings were also
reported by van Rossum et al., showing a correlation be-
tween unsafe feelings related to the risk of PML, and
anxiety in MS patients treated with NTZ [32].
Adherence to treatment reached values above 90% in
the IFN B 1B group at each time point, which is greater
than the mean value described in the literature [33-35].
Also, a relatively high proportion of patients persisted on
treatment in both groups (IFN B 1B nearly 80% vs NTZ
90%), similarly to the findings from larger trials that evalu-
ated MS therapies over similar timeframes [36,37]. An as-
sociation between adherence to disease modifying agents
and MS patients’ clinical outcome has been outlined in
several works, with lower risks of relapses, hospitalizations
and reduced quality of life in patients with regular intake
of medications [35,38].
The main limitation of our study is represented by the
small sample size. High retention and adherence to IFN
B 1B treatment may reflect a bias of a patient sub-
population that is willing to participate in a clinical
study. Moreover, our sample of patients is fully represen-
tative of the MS patient population treated with NTZ in
southern Switzerland as all patients receiving NTZ in
this region are treated at our site, and clinical and radio-
logical characteristics of the patients included in the
study were similar to remaining NTZ treated patients at
our site (data not shown). Moreover, we postulate that
our study population is well representative of a typical
NTZ treated population as included patients experi-
enced over 90% reduction of annualized relapse rate
under NTZ treatment compared to the two years before
NTZ initiation, which is in line with the known efficacy
of NTZ in active MS patients [39,40]. A second limita-
tion of this sub-analysis is represented by the lack of
specific scales for assessment of mood disorders, even
though the FAMS questionnaire includes items related
to physiological wellness. In addition, cognitive outcome
should be considered with caution since we evaluated
only the most frequent cognitive dysfunctions in MS
(working memory, sustained attention, and information
processing speed) using a single test (PASAT) as meas-
ure of cognitive impairment. Albeit, this test is a vali-
dated instrument widespread applied as screening test in
MS clinical research. Finally, the study lacks a placebo
arm, which was avoided for ethical reasons. These limi-
tations may be partially mitigated by the randomized,
prospective design with quarterly MRI monitoring.
In conclusion, our study suggests that de-escalation
to IFN B 1B at NTZ cessation is feasible, well accepted
and tolerated by the majority of patients, and seems to
be associated with substantial stability of cognitive and
fatigue parameters.
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